Innovent Biologics Sustainability Profile
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy. Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.
DitchCarbon Score
How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovent Biologics's score of 40 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innovent Biologics's reported carbon emissions
In 2024, Innovent Biologics reported total carbon emissions of approximately 14,115,290 kg CO2e, with Scope 1 emissions at about 47,780 kg CO2e and Scope 2 emissions at around 14,067,510 kg CO2e. This represents a decrease from 2023, where total emissions were approximately 15,894,420 kg CO2e, comprising about 65,170 kg CO2e in Scope 1 and approximately 15,829,250 kg CO2e in Scope 2. In 2022, the company recorded total emissions of about 22,302,950 kg CO2e, with Scope 1 emissions at approximately 66,740 kg CO2e and Scope 2 emissions at around 22,236,210 kg CO2e. The trend indicates a significant reduction in emissions over the years, particularly from 2022 to 2024. Innovent Biologics has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or climate pledges. The emissions data is sourced directly from Innovent Biologics, Inc., with no cascaded data from a parent or related organization. The company continues to focus on its operational emissions, primarily in Scopes 1 and 2, as part of its commitment to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 60,540 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 15,934,330 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Innovent Biologics's Industry?
How Carbon Intensive is Innovent Biologics's Location?
Innovent Biologics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Innovent Biologics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
